Tuberculosis (TB) remains one of Pakistan’s most serious public health emergencies — and the BCG (Bacillus Calmette-Guérin) vaccine is still the single most widely used tool to prevent its most dangerous forms in children. But BCG’s story doesn’t end with TB. The same century-old vaccine is now a standard cancer therapy for bladder cancer and is being studied as a treatment for type 1 diabetes.
This guide covers everything a parent, patient, or healthcare consumer in Pakistan needs to know: the real scale of TB in Pakistan, how BCG fits into the national immunization program, and BCG’s newer medical applications — with sourced references and answers to the most commonly asked questions.
1. The Burden of Tuberculosis in Pakistan: How Big Is the Problem?
Pakistan is not a minor player in the global TB epidemic — it is one of the countries driving it.
- According to the WHO Global Tuberculosis Report 2025, Pakistan recorded an estimated 670,000 TB cases in 2024, accounting for 6.3% of the world’s total TB burden. This places Pakistan among the top five TB-burden countries globally, alongside India, Indonesia, the Philippines, and China.
- Pakistan carries the largest share of TB cases in the entire WHO Eastern Mediterranean Region, contributing roughly 73% of the region’s TB burden, and ranks as the 5th most TB-affected country in the world.
- WHO and Pakistan’s Ministry of National Health Services estimate that TB affects over 669,000 people and causes approximately 51,000 deaths every year in the country — that works out to roughly 140 deaths per day and over 1,800 new cases arising daily.
- Nationally, TB prevalence, incidence, and mortality rates are estimated at approximately 348, 276, and 34 per 100,000 population per year, respectively (National TB Control Program / NIH Pakistan figures).
- Globally, the reduction in TB incidence between 2015 and 2024 was only about 12%, far short of the WHO End TB Strategy’s milestone of a 50% reduction by 2025 — and Pakistan’s progress mirrors this shortfall.
Where is the burden highest?
TB is not evenly distributed across Pakistan. A subnational burden-estimation study conducted with Pakistan’s National TB Programme found incidence ranging from about 110 to 462 cases per 100,000 people depending on the district, with the highest provincial burden in Sindh (≈292/100,000), followed by Khyber Pakhtunkhwa (≈269/100,000) and Punjab (≈243/100,000). Case detection rates were below 70% in three-quarters of districts studied — meaning a large share of people with TB are never diagnosed or officially counted, largely due to poverty, stigma, weak surveillance, and limited access to rapid diagnostic testing.
Drug-resistant TB is a growing threat
Pakistan is also listed among the high-burden countries for multidrug-resistant and rifampicin-resistant TB (MDR/RR-TB), a form of the disease that is harder, longer, and more expensive to treat, and carries a higher risk of death if untreated.
Why this matters: TB is preventable and curable, yet it continues to kill more people in Pakistan than almost any other infectious disease. Vaccination of infants, early diagnosis, and completing treatment are the three pillars that reduce this burden — and BCG vaccination is the first line of defense, given to every child at birth.
2. TB Prevention in Pakistan: The Layered Approach
No single intervention eliminates TB. Pakistan’s National TB Control Program (NTP) and WHO EMRO rely on a combination of strategies:
- BCG vaccination at birth — protects infants and young children against the most severe, life-threatening forms of TB (TB meningitis and disseminated/miliary TB).
- Active case finding and rapid diagnostics — expanding molecular tests (like GeneXpert) so people are diagnosed faster and more accurately.
- Directly Observed Treatment, Short-course (DOTS) — ensuring patients complete their full anti-TB drug regimen to prevent relapse and drug resistance.
- Contact tracing and preventive therapy — testing and treating household contacts of TB patients, especially children and immunocompromised individuals, before they develop active disease.
- Nutrition and socioeconomic support — because malnutrition and overcrowding are major risk multipliers for TB transmission in Pakistan.
- Infection control in healthcare and congregate settings.
Of these, BCG vaccination is the only one that is preventive at the population level from birth, which is why it has been part of Pakistan’s routine immunization schedule since the program’s inception.
3. What Is the BCG Vaccine?
BCG is a live attenuated (weakened) vaccine made from a laboratory-weakened strain of Mycobacterium bovis, a close relative of the bacterium that causes human TB (Mycobacterium tuberculosis). It was developed in the early 20th century by French scientists Albert Calmette and Camille Guérin — hence the name Bacillus Calmette-Guérin.
What BCG protects against:
- It is most protective against severe, disseminated childhood TB — particularly TB meningitis and miliary TB — both of which can be fatal or cause permanent disability in infants.
- Its protection against adult pulmonary (lung) TB is more variable and less complete, which is why global research continues into next-generation TB vaccines. Still, at the population level, universal infant BCG vaccination remains one of the most cost-effective public health interventions available.
How it’s given: BCG is administered as a single intradermal (into the skin, not muscle) injection, typically in the upper right arm, ideally within the first days to weeks of life.
4. BCG as Part of Pakistan’s Expanded Programme on Immunization (EPI)
Pakistan’s Expanded Programme on Immunization (EPI) was launched in 1978, initially designed to protect children against tuberculosis, poliomyelitis, diphtheria, pertussis, tetanus, and measles. Over the decades it has expanded to cover 12+ vaccine-preventable diseases, including Hepatitis B (2002), Hib (2009), pneumococcal disease (2012), rotavirus (2017), and typhoid (2019–2022).
BCG has been part of EPI Pakistan since day one, and it remains dose one of the routine schedule:
| Vaccine | Protects against | Timing |
|---|---|---|
| BCG | Childhood tuberculosis (severe forms) | At birth (single dose, intradermal) |
| OPV-0 / OPV1–3 | Poliomyelitis | Birth, 6, 10, 14 weeks |
| Pentavalent (DTP-HepB-Hib) | Diphtheria, Pertussis, Tetanus, Hepatitis B, Hib | 6, 10, 14 weeks |
| PCV | Pneumococcal disease | 6, 10, 14 weeks |
| IPV | Poliomyelitis | 14 weeks |
| Rotavirus | Rotavirus diarrhea | 6, 10 weeks |
| Measles & Rubella (MR) | Measles, Rubella | 9 months, 15 months |
Under Pakistan’s National Immunization Policy 2022, a child is only classified as a “Fully Immunized Child” (FIC) if they have received their BCG dose at birth along with the other scheduled vaccines before 12 months of age — underscoring how central BCG is to the definition of complete childhood immunization in Pakistan.
EPI targets roughly 7.5 million children and 5.5 million pregnant women annually across Pakistan, delivered through fixed health facility sites and outreach vaccination teams, including in private-sector clinics.
Practical note for parents in Pakistan: If your baby has missed the birth-dose window, BCG can still be given later in infancy — speak to your pediatrician or vaccination provider about catch-up scheduling rather than skipping it altogether.
5. Beyond TB: The Oncological Use of BCG (Bladder Cancer Immunotherapy)
One of the most remarkable second lives of any vaccine belongs to BCG. Since 1976, intravesical (instilled directly into the bladder) BCG has been the gold-standard adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC) — including high-grade tumors and carcinoma in situ.
How does a TB vaccine treat cancer?
The exact mechanism is still being fully mapped, but current understanding includes several complementary pathways:
- Direct tumor cell interaction: BCG attaches to bladder urothelial and tumor cells via fibronectin attachment protein and integrin receptors, gets internalized, and is presented to the immune system, turning tumor cells into signal generators for an anti-tumor immune response.
- Innate and adaptive immune activation: BCG instillation triggers an intense local inflammatory response — recruiting granulocytes, monocytes, natural killer cells, and B and T lymphocytes into the bladder wall.
- Th1-driven cytotoxic response: A strong CD4+ T-helper type 1 (Th1) response, with high levels of interferon-gamma, TNF-alpha, and IL-2, has repeatedly been linked to better outcomes and lower recurrence.
- Direct cytotoxicity: BCG can induce apoptosis (programmed cell death) in tumor cells directly, through caspase-dependent pathways and oxidative stress.
Clinical impact
Standard treatment is a course of six weekly intravesical BCG instillations following surgical resection of the tumor (TURBT), often followed by “maintenance” instillations over 1–3 years. This regimen meaningfully reduces tumor recurrence and slows progression to muscle-invasive disease compared to surgery alone — though 30–50% of patients still relapse within five years, which is why researchers continue to explore genetically modified recombinant BCG strains and combination therapies to improve response rates.
Why this matters in Pakistan: As bladder cancer awareness and urology services expand, patients and families should know that the same vaccine given to newborns for TB prevention is, in a completely different formulation and dosing route, an established cancer therapy — a good example of how vaccine platforms can be repurposed for immuno-oncology.
6. Emerging Research: BCG and Type 1 Diabetes (T1D)
A third and newer frontier for BCG is autoimmune disease — specifically type 1 diabetes, where the body’s own immune system destroys insulin-producing pancreatic beta cells.
The science behind it
Research led by Dr. Denise Faustman and colleagues at Massachusetts General Hospital (MGH) / Harvard Medical School, funded substantially by the Iacocca Foundation, is built on the idea that BCG can:
- Stimulate the innate immune system to produce tumor necrosis factor (TNF), which may help eliminate the specific autoreactive immune cells that attack the pancreas.
- Gradually shift regulatory T-cell (Treg) gene expression toward a pattern seen in people without type 1 diabetes, over repeated dosing.
- Correct underlying defects in glucose metabolism (aerobic glycolysis) in white blood cells that are believed to contribute to autoimmune attack.
What the trials have shown so far
- A 2012 proof-of-concept, randomized, placebo-controlled trial in adults with long-standing type 1 diabetes found that BCG-treated participants showed meaningful, transient changes in autoimmune markers and insulin-related measures (C-peptide) compared to placebo.
- Phase I follow-up data (published 2018) showed lasting, statistically significant reductions in HbA1c (long-term blood sugar control) in BCG-treated participants that persisted through eight years of follow-up.
- Open-label trials using multi-dose, low-dose BCG regimens (typically five to six doses of a potent BCG strain, unlike the single dose used for TB prevention) reported HbA1c reductions of roughly 10–15% in adults with early-onset type 1 diabetes.
- A notable side finding: in Phase II/III trials conducted during the COVID-19 pandemic, BCG-vaccinated type 1 diabetics who had never previously received BCG showed significant protection against COVID-19 and other infections — with efficacy comparable to mRNA vaccines in the earlier, more lethal phase of the pandemic, and durable protection over a 34-month follow-up.
- As of 2025, MGH’s Faustman Lab has completed a 150-patient Phase II randomized, placebo-controlled trial and is running further pediatric trials (ages 8–17) — data from these are still being analyzed and published, and BCG is not yet an approved standard-of-care treatment for type 1 diabetes.
Important caveat: This research is genuinely promising but still investigational. BCG for type 1 diabetes uses a different dosing regimen (multiple doses of a specific potent strain) from the single birth-dose TB vaccine given through EPI, and it should not be interpreted as something to self-administer or substitute for standard insulin therapy and diabetes management. Anyone interested in these trials should look into formal clinical trial enrollment (e.g., via the Faustman Lab or ClinicalTrials.gov) rather than off-label use.
7. Is BCG Safe? What to Expect After Vaccination
BCG has one of the longest safety track records of any vaccine still in global use, having been administered to billions of infants since the 1920s.
Common, expected reactions (TB prevention dose):
- A small red bump at the injection site that may blister, ulcerate, and heal slowly over weeks to months, eventually leaving a small permanent scar — this is a normal, expected part of the immune response, not a complication.
- Mild swelling of the nearest lymph node (usually in the armpit) is occasionally seen and is usually self-limiting.
Less common: Larger abscesses or persistent lymph node swelling requiring medical review — parents should have any unusual, large, or non-healing reaction assessed by their vaccination provider.
For intravesical BCG (bladder cancer treatment): Local urinary symptoms — frequency, urgency, mild hematuria (blood in urine), and flu-like malaise — occur in a meaningful minority of patients and are managed by the treating urologist. Rare but serious systemic complications (“BCG-itis,” including BCG-related pneumonitis, hepatitis, or disseminated infection) occur in a small percentage of cases and require prompt medical attention, which is why intravesical BCG is always administered and monitored by a specialist.
Who should generally avoid BCG: Individuals who are significantly immunocompromised (including advanced HIV, certain cancers, or immunosuppressive therapy) should not receive live BCG vaccine — this should always be discussed with a physician.
8. Book Your Child’s BCG Vaccination (and Full EPI Schedule) with Vaccine.pk
TB prevention starts in the first days of life. Vaccine.pk clinics offer:
- On-schedule BCG vaccination at birth, administered by trained clinical staff following national EPI guidelines.
- Catch-up BCG dosing for infants who missed the birth-dose window.
- The complete EPI schedule (Pentavalent, PCV, OPV/IPV, Rotavirus, Measles-Rubella) tracked and reminded to you, so no dose is missed.
- Digital vaccination records and printable immunization certificates for school, travel, or visa purposes.
👉 Book your child’s BCG and EPI vaccinations at Vaccine.pk today — protecting your child against tuberculosis is one of the simplest, most effective decisions you can make in their first week of life.
Frequently Asked Questions (FAQs)
1. Is BCG vaccination compulsory in Pakistan? BCG is part of Pakistan’s routine EPI schedule and is strongly recommended for every newborn. While not criminally “compulsory,” it is considered an essential, standard-of-care vaccination and is required for a child to be classified as “fully immunized” under national policy.
2. At what age should a baby get the BCG vaccine? Ideally within the first few days after birth, alongside the birth dose of OPV. If missed, it can still be given later in infancy — talk to your provider about catch-up timing.
3. Does BCG completely prevent TB? No vaccine offers 100% protection. BCG is most effective at preventing severe, life-threatening forms of childhood TB, such as TB meningitis and miliary TB. Its protection against adult pulmonary TB is more variable, which is why case detection, treatment, and public health measures remain essential alongside vaccination.
4. Why does the BCG injection site leave a scar? The small ulcer and eventual scar are a normal sign that the immune system has responded to the vaccine. It typically develops over several weeks and is not a cause for concern unless it becomes unusually large, doesn’t heal, or is accompanied by significant lymph node swelling — in which case you should consult your vaccinator.
5. Can adults get BCG vaccination in Pakistan? BCG is primarily given as a single infant dose. Adult (re-)vaccination for TB prevention is not part of routine practice in most settings; however, BCG is separately used in adults in a completely different context — as a bladder cancer treatment — under a urologist’s supervision.
6. What is BCG used for besides TB? Beyond tuberculosis prevention, BCG is an established treatment for non-muscle-invasive bladder cancer, delivered directly into the bladder (intravesical instillation). It is also being studied in clinical trials as a potential treatment to help regulate the immune system in type 1 diabetes.
7. Is the BCG-for-diabetes treatment available in Pakistan? No — BCG for type 1 diabetes remains investigational and is currently being studied through formal clinical trials, primarily in the United States (Massachusetts General Hospital / Faustman Lab). It is not an approved standard treatment anywhere yet, and people with type 1 diabetes should continue their prescribed insulin and diabetes management plan.
8. How big is the TB problem in Pakistan compared to other countries? Pakistan is the world’s 5th highest TB-burden country, contributing about 6.3% of all global TB cases (WHO Global TB Report 2025), and carries the largest TB burden within the WHO Eastern Mediterranean Region.
9. What are the symptoms of TB that should prompt testing? Persistent cough lasting more than 2–3 weeks, unexplained weight loss, night sweats, low-grade fever, and fatigue are classic warning signs. Anyone with these symptoms — especially with a known TB contact — should get tested promptly rather than waiting.
10. Where can I get my child’s BCG and other EPI vaccines administered professionally? You can book BCG and the full EPI vaccination schedule through Vaccine.pk, with trained staff, proper cold-chain-handled vaccines, and digital vaccination records.
References
- World Health Organization. Global Tuberculosis Report 2025. WHO, 2025. https://cdn.who.int/media/docs/default-source/global-tuberculosis-report-2025/global-tb-report-2025_factsheet.pdf
- “Pakistan among top five countries contributing 6.3pc of global TB cases: WHO.” The News International, November 2025. https://www.thenews.com.pk/latest/1357766-pakistan-among-top-five-countries-contributing-6-3pc-of-global-tb-cases-who
- WHO Regional Office for the Eastern Mediterranean (EMRO). “Tuberculosis kills 140 people per day in Pakistan, WHO and the Ministry of Health join forces to intensify action.” March 2026. https://www.emro.who.int/pak/pakistan-news/tuberculosis-kills-140-people-per-day-in-pakistan-who-and-the-ministry-of-health-join-forces-to-intensify-action.html
- National Institutes of Health (NIH), Islamabad, Pakistan. “National TB Control Program.” http://www.nih.org.pk/national-tb-control-program
- Qadeer, E. et al. “Subnational tuberculosis burden estimation for Pakistan.” PLOS Global Public Health, 2024. https://journals.plos.org/globalpublichealth/article?id=10.1371%2Fjournal.pgph.0003653 (also available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419375/)
- “Further analysis of tuberculosis in eight high-burden countries based on the Global Burden of Disease Study 2021 data.” PMC, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440896/
- Federal Directorate of Immunization, Pakistan. “Immunization Schedule.” https://www.epi.gov.pk/immunization-schedule/
- Government of Pakistan, Ministry of National Health Services. National Immunization Policy 2022. https://www.epi.gov.pk/wp-content/uploads/2023/01/NationalImmunizationPolicy2022-compressed.pdf
- WHO EMRO. “Expanded Programme on Immunization — Pakistan.” https://www.emro.who.int/pak/programmes/expanded-programme-immunization.html
- Government of the Punjab, Primary & Secondary Healthcare Department. “Expanded Program Immunization.” https://pshealthpunjab.gov.pk/Home/VerticalProgramImmunization
- Kamat, A.M. et al. “BCG in Bladder Cancer Immunotherapy.” PMC, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264881/
- “Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma.” PMC, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763876/
- “Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer.” PubMed, 2024. https://pubmed.ncbi.nlm.nih.gov/39206898/
- “Role of urothelial cells in BCG immunotherapy for superficial bladder cancer.” PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364784/
- “BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4+ Th1 responses.” PMC, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12877854/
- Faustman, D.L. et al. “Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes.” PLOS ONE, 2012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414482/ ; https://pubmed.ncbi.nlm.nih.gov/22905105/
- Kuhtreiber, W. et al. “881-P: BCG Clinical Trial Programs in Advanced Type 1 Diabetes — 2025 Update.” Diabetes, American Diabetes Association, 2025. https://diabetesjournals.org/diabetes/article/74/Supplement_1/881-P/159629/
- Massachusetts General Hospital. “Further hope for BCG vaccine in stemming type 1 diabetes.” 2021. https://www.massgeneral.org/news/press-release/further-hope-for-bcg-vaccine-in-stemming-type-one-diabetes
- Massachusetts General Hospital. “Century-old vaccine protects type 1 diabetics from infectious diseases.” 2024. https://www.massgeneral.org/news/press-release/century-old-vaccine-protects-type-1-diabetics
- Faustman Lab, Massachusetts General Hospital. “Clinical Trials.” https://faustmanlab.org/clinical-trials/
- ClinicalTrials.gov. “Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes” (NCT02081326). https://clinicaltrials.gov/study/NCT02081326
This article is for general educational purposes and does not replace professional medical advice. For TB symptoms, diagnosis, or treatment, consult a qualified physician or your nearest National TB Control Program facility. For BCG and EPI vaccination bookings, visit Vaccine.pk.
About admin
Healthcare professional and writer passionate about child health and vaccination awareness.
View all posts by admin
Leave a Reply